ArticleActa diabetologica2026
Clinical significance and biological role of circFNDC3B in diabetic retinopathy.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis paper investigates the clinical significance and role of circFNDC3B in diabetic retinopathy (DR).
methodsExpression levels of circFNDC3B, miR-578, and PIK3CA were detected in serum from DR patients and in HRMECs under high glucose (HG) conditions via qRT-PCR. Diagnostic value of circFNDC3B were assessed using ROC curves and logistic regression analysis. Cell proliferation, migration, and invasion capabilities of HRMECs were assessed using CCK-8 assays and Transwell experiments. Cellular inflammation was measured via ELISA. The interrelationship among circFNDC3B, miR-578, and PIK3CA was validated through dual-luciferase reporter and RNA immunoprecipitation experiments.
resultsIn the serum of patients with DR, circFNDC3B was markedly upregulated, and it has potential as a diagnostic biomarker for DR. miR-578 was identified as a direct target miRNA of circFNDC3B, showing downregulated expression in both DR patient serum and HG-induced HRMECs. Inhibition of miR-578 partially reversed the suppression of circFNDC3B downregulation on proliferation, migration, invasion, and inflammatory responses in HG-induced HRMECs circFNDC3B regulated PIK3CA expression by sponging miR-578.
conclusioncircFNDC3B may serve as a potential biomarker for DR diagnosis and treatment. Its involvement in HG-induced HRMEC injury, through interacting with miR-578, provides new insights into the pathogenesis of DR.
Indexed as
Identifiers
42862339What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.